Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.
OncoSil Medical has completed the Last Patient, Last Visit milestone in its TRIPP-FFX clinical trial, a prospective multi-centre study assessing the safety and efficacy of the OncoSil™ device when used alongside FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer. With 88 patients enrolled across 15 sites in Europe and Australia, the company will now move to final data cleaning, database lock and statistical analysis, and plans to present results in the first half of 2026, followed by a regulatory submission in the second half of 2026 to extend its CE Mark to include use with FOLFIRINOX. Together with completion of the PANCOSIL investigator-initiated study, this marks the end of a major phase of clinical investment in this indication and positions OncoSil to concentrate on regulatory engagement, potential label expansion and broader commercial execution, potentially giving clinicians more flexibility to integrate the device into standard treatment pathways for a high unmet-need cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company in the interventional oncology sector, focused on improving outcomes for patients with unresectable locally advanced pancreatic cancer. Its core product, the OncoSil™ device, delivers targeted intratumoural Phosphorous-32 (32P) microparticles in addition to chemotherapy, enabling higher local radiation doses while sparing surrounding organs. The device holds CE Marking in the EU and UK, breakthrough device designation in Europe and the US, and is approved in more than 30 countries, with commercial use already underway across several European markets and Israel.
Average Trading Volume: 23,400
Technical Sentiment Signal: Sell
Current Market Cap: A$14.36M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.